WO1997002033A1 - Agent uricosurique - Google Patents
Agent uricosurique Download PDFInfo
- Publication number
- WO1997002033A1 WO1997002033A1 PCT/JP1996/001801 JP9601801W WO9702033A1 WO 1997002033 A1 WO1997002033 A1 WO 1997002033A1 JP 9601801 W JP9601801 W JP 9601801W WO 9702033 A1 WO9702033 A1 WO 9702033A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- general formula
- salt
- hydantoin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
Definitions
- the present invention relates to a novel hydantoin derivative and a uric acid excreting agent containing a hydantoin derivative, which is effective for treating or preventing and treating purine metabolism disorders such as hyperuricemia and gout.
- gout attacks For the prevention and treatment of hyperuricemia and gout, conventional treatments for gout attacks, such as colchicine, analgesic and anti-inflammatory drugs such as indomethacin and phenylbuzozone, and uric acid excretion such as probenecid, benzbromarone, and sulfinpiraban Agents and uric acid synthesis inhibitors such as aropurinol are used.
- these drugs have problems such as restrictions on use and side effects as described below, and it has been desired to develop effective and safe preventive / therapeutic drugs for the disease.
- JP-A-62-16705, JP-A-4-128266 and JP-A-3-294702 disclose 1- (2,5-dichlorophenylsulfonyl).
- sulfonylhydantoin derivatives having, aldose reductase inhibitory action, blood glucose lowering action and Z or lipid lowering action.
- Japanese Patent Application Laid-Open No. Hei 6-212,157 discloses that 1- (3-bromobenzo [b] furan-1-ylsulfonyl) hydantoin exhibits a uric acid excretion effect. There is no disclosure of having a slow diuretic effect. There is no disclosure in any of the technical contents that the compound of the present invention has a uric acid excretion effect.
- An object of the present invention is to solve at least one of the above problems.
- a first embodiment of the present invention provides a compound represented by the general formula (I):
- Q represents a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a 2,5-dimethylcen-3-yl group, an indane-12-yl group, or a 2,5-dichlorophenyl group.
- the present invention relates to a therapeutic agent for hyperuricemia, which comprises a hydantoin derivative represented by the formula or a salt thereof as an active ingredient.
- a therapeutic agent for hyperuricemia in which Q in the general formula (I) is a cyclohexyl group a therapeutic agent for hyperuricemia in which Q in the general formula (I) is a cycloheptyl group
- a therapeutic agent for hyperuricemia in which Q in I) is an indan-12-yl group or a hyperuricemia in which Q in general formula (I) is a 2,5-dichlorophenyl group.
- a second aspect of the present invention is characterized by containing a hydantoin derivative represented by the general formula (I) (wherein Q has the same definition as described above) or a salt thereof as an active ingredient.
- Gout prevention and treatment a preventive / therapeutic agent for gout in which Q in the general formula (I) is a cyclohexyl group, a preventive / therapeutic agent for gout in which Q in the general formula (I) is a cycloheptyl group, the general formula (I) Pain in which 0 is a cyclooctyl group Gout prevention / therapeutic agent, a gout preventive / therapeutic agent in which Q in general formula (I) is 2,5-dimethylcen-3-yl group, Q in general formula (I)
- the present invention relates to a gout preventive / therapeutic agent or a gout preventive / therapeutic agent wherein Q in the general formula (I) is a 2,5-dichlorophen
- a third aspect of the present invention provides a uric acid comprising a hydantoin derivative represented by the general formula (I) (wherein Q has the same definition as described above) or a salt thereof as an active ingredient.
- excretion agents a uric acid comprising a hydantoin derivative represented by the general formula (I) (wherein Q has the same definition as described above) or a salt thereof as an active ingredient.
- uric acid excreting agent in which Q in the general formula (I) is a cyclohexyl group uric acid excreting agent in which Q in the general formula (I) is a cycloheptyl group, and Q in the general formula (I) is a cyclooctyl group
- the present invention relates to a uric acid excreting agent wherein Q in the general formula (I) is a 2,5-dichlorophenyl group.
- a fourth aspect of the present invention provides a compound represented by the following general formula (I ′):
- Q ′ represents a cycloheptyl group, a cyclooctyl group, a 2,5-dimethylchen-13-yl group or an indan-12-yl group) or a salt thereof. That is, a hydantoin derivative or a salt thereof in which Q ′ in the general formula (I ′) is a cycloheptyl group, Q ′ in the general formula (I ′) A hydantoin derivative or a salt thereof in which is a cyclooctyl group; a hydantoin derivative or salt thereof in which Q ′ in the general formula (I ′) is a 2,5-dimethylcen-3-yl group; or Q in the general formula (I ′) 'Relates to a hydantoin derivative or a salt thereof in which' is an indane-2-yl group.
- the salt of the compound (I ′) used in the present invention includes, for example, alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, inorganic bases such as ammonium salt, and benzylamine. Salts, organic base salts such as getylamine salts, and amino acid salts such as arginine salts and lysine salts.
- Q ′ represents a cycloheptyl group, a cyclooctyl group, a 2,5-dimethylcen-3-yl group or an indan-2-yl group
- R represents a hydroxyl group or the number of carbon atoms of methoxy, ethoxy, etc.
- Q ′ represents a cycloheptyl group, a cyclooctyl group, a 2,5-dimethyl-cen-3-yl group or an indane-12-yl group
- Q ′ has the same meaning as described above, or a method for producing the hydantoin derivative or a salt thereof.
- a sixth aspect of the present invention provides a compound of the general formula (II):
- Q ′ represents a cycloheptyl group, a cyclooctyl group, a 2,5-dimethylcen-3-yl group or an indane-12-yl group
- R is a hydroxyl group or a carbon number of methoxy, ethoxy, etc. Which represents 1 to 4 alkoxy groups).
- the sixth embodiment of the present invention is useful as an intermediate for producing the hydantoin derivative represented by the general formula (I ′) according to the fourth embodiment of the present invention.
- a seventh aspect of the present invention provides a method for producing a drug as a therapeutic agent for hyperuricemia, a therapeutic agent for gout and / or a drug as a uric acid excretory agent, wherein Q is as defined above. Which represents the same definition) or a salt thereof.
- a hydantoin derivative or a salt thereof in which Q in the general formula (I) is a cyclohexyl group, and Q in the general formula (I) is a cycloheptyl group Use of a hydantoin derivative or a salt thereof, use of a hydantoin derivative or a salt thereof in which Q in the general formula (I) is a cyclooctyl group, use of a hydantoin derivative or a salt thereof in the general formula (I)
- Use of a hydantoin derivative or a salt thereof, use of a hydantoin derivative or a salt thereof in which Q in the general formula (I) is an indane-2-yl group, or Q in the general formula (I) is a 2,5-dichlorophenyl group A use of a hydantoin derivative or a salt thereof.
- an eighth aspect of the present invention is a method for treating hyperuricemia with an effective amount of a hydantoin derivative represented by the general formula (I) (wherein Q has the same definition as described above) or a salt thereof. And how to prevent or treat gout or gout.
- a method for treating hyperuricemia and / or preventing and treating gout a method for treating hyperuricemia in which Q in formula (I) is a cyclooctyl group, and a method for treating or preventing Z or gout
- Q of the general formula (I) For treating hyperuricemia in which is an indane-2-yl group and preventing or treating Z or gout, or hyperuricemia in which Q in general formula (I) is a 2,5-dichlorophenyl group
- the present invention relates to a method for treating gout and a method for preventing and treating gout.
- a ninth aspect of the present invention relates to a method for excreting uric acid by an effective amount of a hydantoin derivative represented by the general formula (I) (wherein Q has the same definition as described above) or a salt thereof.
- uric acid in which Q in the general formula (I) is a cyclohexyl group
- uric acid in which Q in general formula (I) is a cycloheptyl group, excluding uric acid in which Q in general formula (I) is a cyclooctyl group
- Q in general formula (I) A method for excreting uric acid, which is a 2,5-dimethylphenyl-3-yl group, a method for excreting uric acid, wherein Q in general formula (I) is an indan-12-yl group, or a general formula (I)
- the present invention relates to a method for excreting uric acid, wherein Q is a 2,5-dichlorophenyl group.
- Q represents a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a 2,5-dimethylcen-3-yl group, an indane-12-yl group or a 2,5-dichlorophenyl group
- a cyclohexyl group, a cycloheptyl group, a 2,5-dimethylcen-3-yl group or an indane-12-yl group is preferable, and a cycloheptyl group is more preferable.
- Q' is a cycloheptyl group, a cyclooctyl group, a 2,5-dimethylcen-3-yl group or an indane-12-yl group.
- a cycloheptyl group is preferred.
- a compound of the formula Q—X (where Q is the same as that of the general formula (I), and X is a halogen atom) may be treated with an appropriate base such as n-butyllithium or metallic lithium to obtain an organic lithium compound or lead to Grignard reagent using metallic magnesium is reacted with sulfur dioxide or halogenated Chioniru, then treated with a suitable oxidizing agent such as a halide ion presence chlorine formula Q- S0 2 -X (Q, X Is the same as the above).
- a method of reacting an organolithium compound or a Grignard reagent with a sulfuryl halide to directly obtain a sulfonyl halide is also effective.
- Cycloargen, indene, Q—X (Q and X have the same meanings as above), etc.
- Q—SY (Q is the same as above, and Y is H and acetyl) , benzyl or S_ ⁇ 3 N a) or Q-S- S- Q (di Surufi de; Q is chlorine gas synonymous) those supra, bromine, potassium chlorate in hydrochloric acid (KC 10 3), etc.
- a suitable halosulfonic agent such as halosulfonic acid is added to the aromatic compound QH in the presence or absence of a pentahalogenated phosphoric acid, in the absence of a solvent, or in a suitable solvent such as methylene chloride.
- a suitable solvent such as methylene chloride.
- the sulfonyl halide and H 2 NCH 2 CO—Z (Z is a C 1 to C 4 alkoxy group such as a hydroxyl group, methoxy, ethoxy, etc. or a C 2 to C 5 alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, etc.)
- Z is a C 1 to C 4 alkoxy group such as a hydroxyl group, methoxy, ethoxy, etc. or a C 2 to C 5 alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, etc.
- a glycine derivative represented by the following formula (1) to synthesize an N-sulfonylglycine derivative.
- the treatment of the product differs depending on the type of the glycine derivative.
- a group of three female Wistar rats (4 weeks old) suspended in 0.5% carboxymethylcellulose sodium aqueous solution or 5% arabia gum aqueous solution 300 or 100 OmgZkg of the compound was orally administered at a liquid volume of 1 Om1Zkg, and immediately saline was orally loaded at 25 ml / kg, and urine was collected up to 5 hours after the administration of the test compound.
- urine uric acid concentration was determined by the method of Kabasakarian et al. (Ka basakalian, P. et. A1: CI in Chem. The urinary uric acid excretion was calculated according to the ELISA method.
- Table 1 shows the relative values of each group when the urine volume and urinary uric acid excretion of the control group to which a 0.5% aqueous solution of sodium carboxymethylcellulose or a 5% aqueous solution of gum arabic was administered in place of the test compound solution were 100. Shown in
- test compounds 1 to 6 in this test are as follows.
- f dagger 3 1— (cyclooctylsulfonyl) hydantoin
- the compound of the present invention is a drug that exhibits a strong uric acid excretion effect in animals while maintaining or alleviating urine volume and has low toxicity, and is used for the treatment of hyperuricemia and gout It can be a medicine that makes sense for prevention and prevention.
- Gout is a disease in which the concentration of uric acid in the blood exceeds a certain level, precipitates as sodium urate, and deposits in the joint space and kidney. Therefore, treating hyperuricemia can prevent gout.
- Examples of the salt of the compound of the general formula (I) used in the present invention include alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, and inorganic salts such as ammonium salt.
- Pharmaceutically acceptable salts such as bases, organic base salts such as benzylamine salt and dimethylamine salt, and amino acid salts such as arginine salt and lysine salt.
- the uric acid excreting agent of the present invention may be prepared by adding at least one of the hydantoin derivative of the general formula (I) or a salt thereof to a suitable pharmaceutically acceptable carrier or solvent, for example, sterile water or vegetable oil, and Appropriate combinations of organic solvents and solubilizers (ethanol, acetic acid, glycerin, propylene glycol, etc.), excipients, binders, lubricants, colorants, flavors, emulsifiers or suspending agents, etc. It can be done.
- a suitable pharmaceutically acceptable carrier or solvent for example, sterile water or vegetable oil, and Appropriate combinations of organic solvents and solubilizers (ethanol, acetic acid, glycerin, propylene glycol, etc.), excipients, binders, lubricants, colorants, flavors, emulsifiers or suspending agents, etc. It can be done.
- dosage forms include tablets, capsules, granules, fine granules, powders, suppositories, syrups, and other oral preparations, inhalants, ointments, aqueous or non-aqueous injections, and milk.
- examples include turbid or suspending injections, or solid injections that are dissolved, emulsified or suspended at the time of use, and are orally or parenterally (eg, rectally administered, It is administered to patients regardless of skin absorption, transmucosal absorption, intravenous administration, intramuscular administration, or subcutaneous administration.
- the daily dose is lmg to 500Omg, preferably 10 to 50Omg in the case of the hydantoin derivative, and ointment. 1 to 10% ointment can be applied in an appropriate amount.Each force can be increased or decreased as appropriate according to the patient's condition, and the total amount is administered once or in 2 to 6 divided doses And continuous administration such as intravenous drip is also possible.
- Boiling point 1 1 3 to 1 15 ° C (14 mmHg)
- Step 1 The compound (200 g) obtained in Step 1 was dissolved in methylene chloride (31), and glycineethyl ester hydrochloride (306.6 g) was added. Then, while stirring under ice-water cooling, triethylamine (321 g) was added. m 1) was added dropwise. After stirring at room temperature for 3.5 hours, the reaction solution was washed successively with water, 1N-hydrochloric acid and saturated saline, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
- Step 3 Preparation of 1- (cyclohexylsulfonyl) thiohydantoin Ammonium thiocyanate (17.8 g) was added to a mixture of the compound obtained in Step 2 (23.5 g) and acetic anhydride (50 ml). In addition, pyridine (22.3 ml) was added dropwise. After stirring at 40-50 ° C for 30 minutes, the reaction solution was poured into water (200 ml) and extracted twice with ethyl acetate (500 ml).
- the compound (52 g) obtained in Step 3 was suspended in acetic acid (520 ml), and the mixture was diluted with 60% of a 30% aqueous hydrogen peroxide solution (68 ml). After stirring for 1 hour, the insolubles were removed by filtration, poured into water (31), and the precipitated crystals were collected by filtration and dried to give the title compound (25 g).
- the results of the analysis are shown as compound 1 in Table 2.
- the obtained crude cycloheptylsulfonyl chloride was added dropwise to a suspension of glycineethyl ester hydrochloride (81 g) and triethylamine (80 ml) in methylene chloride (500 ml) under ice-water cooling. After stirring at room temperature for 2 hours, the reaction solution was washed successively with water, 1N hydrochloric acid and saturated saline, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
- Step 3> Preparation of 1- (cycloheptylsulfonyl) thiohydantoin Pyridine (96 m 1) was added to a mixture of the compound (92.5 g) obtained in Step 2 and ammonium thiocyanate (90 g). Acetic anhydride (185 ml) was slowly added under water cooling. After stirring at 50 to 60 ° C for 3 hours, the reaction solution was poured into 1N-hydrochloric acid (1.51), and the precipitated crystals were collected by filtration. The crystals were dissolved in ethyl acetate (11), washed with water and saturated saline, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was crystallized from ether-hexane and collected by filtration to give the title compound (78 g). Was.
- the compound (78 g) obtained in Step 3 was dissolved in acetic acid (800 ml), and 30% aqueous hydrogen peroxide (96 ml) was slowly added dropwise at 60 ° C. After stirring for 1 hour, insolubles were removed by filtration, the filtrate was poured into water (51), and the precipitated crystals were collected by filtration. The crystals were dissolved in ethyl acetate (11) and washed sequentially with water and saturated saline. After the ethyl acetate layer was dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure.
- Cyclooctene (20 g) is dissolved in anhydrous hexane (100 ml), 2,2'-azobisisobutyronitrile (1.5 g) and thioacetic acid (20 ml) are added, and the mixture is refluxed for 5 hours under an argon atmosphere. did. After allowing the reaction solution to cool, it was poured into water (200 ml) and extracted with ether (200 ml). The ether layer was washed successively with a saturated aqueous solution of sodium hydrogen carbonate and saturated saline, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: hexane) to give the title compound (28 g) as an oil.
- Step 2 Production of N— (cyclooctylsulfonyl) glycine
- the obtained crude cyclooctylsulfonyl chloride was dissolved in methylene chloride (300 ml), glycineethyl ester hydrochloride (56 g) was added, and triethylamine (56 ml) was added dropwise while stirring under ice-water cooling. After stirring at room temperature for 1 hour, the reaction solution was washed successively with water, 1N-hydrochloric acid and saturated saline, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
- Step 3 Production of 1- (cyclooctylsulfonyl) thiohydantoin
- the title compound (10.9 g) was prepared in the same manner as in Step 3 of Example 1 using the compound (14 g) obtained in Step 2. ).
- Production process 1 Production of 2,5-dimethylbenzene 3-sulfonyl chloride
- Phosphorus pentachloride (28 g) was suspended in methylene chloride (50 ml), and chlorosulfonic acid (21 g) was slowly added dropwise under ice-cooling. After stirring for 30 minutes, a methylene chloride solution (25 ml) of 2,5-dimethylthiophene (1 Og) was slowly added dropwise. After stirring for 2 hours, the reaction solution was poured into water (300 ml), and the methylene chloride layer was separated. The aqueous layer was further extracted with methylene chloride (100ml).
- Step 3 Production of 1- (indan-1-ylsulfonyl) thiohydantoin
- the title compound (5.4 g) was prepared in the same manner as in Step 3 of Example 2 using the compound (11 g) obtained in Step 2. ).
- Step 4 Production of 1- (indan-1-ylsulfonyl) hydantoin Using the compound (5.3 g) obtained in Step 3, the title compound (2.8 g) was prepared in the same manner as in Step 4 of Example 1 I got The analytical data is shown as compound 5 in Table 2.
- Step 1> Preparation of N- (2,5-dichloromouth phenylsulfonyl) glycine Anhydrous potassium carbonate (17 g) was dissolved in 5 Oml of purified water, and glycine (9.3 g) was added and dissolved. To this was added 2,5-dichloromouth phenylsulfonyl chloride (25 g), heated at 40-50 ° C for 10 minutes, and further heated in a boiling water bath for 1 hour. After cooling, 2 N hydrochloric acid was added to make the solution acidic (pH 2-3), and the resulting precipitate was collected by filtration to obtain the title compound (28.1).
- Step 2 > 1— (2,5-dichlorophenylsulfonyl) thiohydantoin
- the compound obtained in Step 1 (11.5 g) is added to anhydrous pyridine (3.3 m 1), dried ammonium thiocyanate ( After adding 6.1 g) and acetic anhydride (8.2 ml), the mixture was heated in a boiling water bath for 30 minutes with stirring. After cooling, 8 Oml of purified water was added, and the mixture was ice-cooled. The resulting precipitate was collected by filtration to obtain the title compound (7.4 g).
- Step 3 > 1— (2,5-Dichloromouth phenylsulfonyl) Production of hydantoin 50% (volume by volume) nitric acid 10 Om l to the compound (1 3.3 g) obtained in Step 2 was added, and the mixture was heated in a boiling water bath for 90 minutes. After cooling with ice, the resulting precipitate was collected by filtration to obtain the title compound (5.1 g).
- the analytical data is shown in Table 2 as compound 6.
- the above analysis data is based on the NMR data of JEOL FX90A (JE ⁇ L FX 9 OA) FT-NMR (* is shown on the data, manufactured by JEOL Ltd.) or JEOL JN1V [—EX 270 (JEOL JNM-EX 270) ) FT—NMR (manufactured by JEOL Ltd.), IR: HORIBA FT—200 (manufactured by Horiba, Ltd.), melting point: Me tt 1er FP 80 or The measurement was performed using FP 90 (both manufactured by METRA-I Co., Ltd.).
- tablets having a weight of 20 O mg are prepared in the same manner as in Example A.
- compound 4 lactose, corn starch, and crystalline cellulose are uniformly mixed, and an aqueous solution of hydroxypropyl cellulose is further added, and granules are prepared by a wet granulation method. The granules are dried and sized to form granules.
- Compound 3 is thoroughly polished in a mortar to give a fine powder, and then made into rectal suppositories in 1 g portions by a melting method.
- the uric acid excretion agent of the present invention has a strong uric acid excretion effect in an animal experimental model, while maintaining or alleviating urine volume and having low toxicity, and is used for treating hyperuricemia or gout. And useful for prevention.
- the effect of maintaining or moderately increasing urine volume by the uric acid excreting agent of the present invention is expected to reduce the burden on patients when a large amount of water is ingested.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU62429/96A AU6242996A (en) | 1995-06-30 | 1996-06-28 | Uricosuric agent |
EP96921119A EP0788796A1 (en) | 1995-06-30 | 1996-06-28 | Uricosuric agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7/166210 | 1995-06-30 | ||
JP16621095 | 1995-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997002033A1 true WO1997002033A1 (fr) | 1997-01-23 |
Family
ID=15827147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1996/001801 WO1997002033A1 (fr) | 1995-06-30 | 1996-06-28 | Agent uricosurique |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0788796A1 (ja) |
AU (1) | AU6242996A (ja) |
CA (1) | CA2197568A1 (ja) |
WO (1) | WO1997002033A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7423176B2 (en) * | 2004-04-13 | 2008-09-09 | Cephalon, Inc. | Bicyclic aromatic sulfinyl derivatives |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58109418A (ja) * | 1981-12-23 | 1983-06-29 | Jun Okuda | アルド−スレダクタ−ゼの阻害剤 |
JPS6267075A (ja) * | 1985-09-19 | 1987-03-26 | Mochida Pharmaceut Co Ltd | ヒダントイン誘導体及びそれを有効成分とするアルド−スレダクタ−ゼ阻害剤 |
JPS6322565A (ja) * | 1986-07-02 | 1988-01-30 | アメリカン・ホ−ム・プロダクツ・コ−ポレイシヨン | アルド−スレダクタ−ゼ抑制剤として有用なナフタレニルスルホニルイミダゾリジンジオンおよびそのチオキソ類似体 |
JPH04128266A (ja) * | 1988-08-24 | 1992-04-28 | Mochida Pharmaceut Co Ltd | ヒダントイン誘導体及びそれを有効成分とする医薬組成物 |
-
1996
- 1996-06-28 AU AU62429/96A patent/AU6242996A/en not_active Abandoned
- 1996-06-28 EP EP96921119A patent/EP0788796A1/en not_active Withdrawn
- 1996-06-28 WO PCT/JP1996/001801 patent/WO1997002033A1/ja not_active Application Discontinuation
- 1996-06-28 CA CA 2197568 patent/CA2197568A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58109418A (ja) * | 1981-12-23 | 1983-06-29 | Jun Okuda | アルド−スレダクタ−ゼの阻害剤 |
JPS6267075A (ja) * | 1985-09-19 | 1987-03-26 | Mochida Pharmaceut Co Ltd | ヒダントイン誘導体及びそれを有効成分とするアルド−スレダクタ−ゼ阻害剤 |
JPS6322565A (ja) * | 1986-07-02 | 1988-01-30 | アメリカン・ホ−ム・プロダクツ・コ−ポレイシヨン | アルド−スレダクタ−ゼ抑制剤として有用なナフタレニルスルホニルイミダゾリジンジオンおよびそのチオキソ類似体 |
JPH04128266A (ja) * | 1988-08-24 | 1992-04-28 | Mochida Pharmaceut Co Ltd | ヒダントイン誘導体及びそれを有効成分とする医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
CA2197568A1 (en) | 1997-01-23 |
AU6242996A (en) | 1997-02-05 |
EP0788796A1 (en) | 1997-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS6035350B2 (ja) | 右旋性スピローヒダントイン | |
JP2007302658A (ja) | イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法 | |
EA009985B1 (ru) | Новый способ получения рофлумиласта | |
KR100436254B1 (ko) | N-메틸-n[(1s)-1-페닐-2-((3s)-3-하이드록시피롤리딘-1-일)에틸]-2,2-디페닐아세트아미드 | |
WO2014032583A1 (zh) | 一种硒唑甲酸类化合物及其制备方法和用途 | |
JPH059424B2 (ja) | ||
JPH0222271A (ja) | 共役γ−オキシブテノライド化合物およびこれを有効成分とする抗潰瘍剤 | |
WO1997026242A1 (fr) | Derives de 3-(bis-phenylmethylene substitue) oxindole | |
CA2433190C (en) | Amlodipine hemimaleate | |
WO1997002033A1 (fr) | Agent uricosurique | |
JPS6219577A (ja) | 新規なベンジルピペラジン誘導体および該化合物を有効成分とする医薬組成物 | |
JPS6241234B2 (ja) | ||
WO1998054131A1 (fr) | Nouveaux derives sulfonamides | |
WO2013083014A1 (zh) | 黄豆苷元衍生物、其药学上可接受的盐、制备方法以及包含其的药物组合物 | |
JP7426756B2 (ja) | チオベンゾピラン系化合物及び関節リウマチの治療薬の調製におけるその使用 | |
JPS6324498B2 (ja) | ||
US6316489B1 (en) | Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine | |
EP1163217B1 (en) | New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine | |
JP2007530424A (ja) | 新規N−ヒドロキシ−4−(3−フェニル−5−メチル−イソオキサゾール−4−yl)−ベンゼンスルホンアミドの溶媒和物 | |
HU203839B (en) | Process for producing pharmaceutical composition containing acrylic acid derivatives | |
EP0680321A1 (en) | Lysine salt of 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide | |
JP3928057B2 (ja) | クマリン誘導体 | |
JP4011780B2 (ja) | ジヒドロキノリン誘導体 | |
KR20090090942A (ko) | 신규 결정형의 아토르바스타틴 헤미칼슘 | |
JPH06506208A (ja) | 新規チオフェン−2−カルボン酸誘導体およびそれらの製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2197568 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996921119 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1997 793663 Country of ref document: US Date of ref document: 19970227 Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1996921119 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996921119 Country of ref document: EP |